Loading
Chronic Obstructive Pulmonary Disease (COPD) Research · Journal article
Healthcare · July 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a published protocol for a registered, monocentric randomized controlled trial of a multidisciplinary telemedicine and wearable-device-assisted smoking cessation program versus standard in-person care. No trial results, preliminary or final, are presented; the document announces intended study design, comparisons, and planned endpoints only.
Monocentric, randomized controlled trial (protocol stage). Adults who smoke combustible or heated tobacco or electronic nicotine delivery systems. Intervention: Multidisciplinary telemedicine-based smoking cessation program assisted by wearable remote-monitoring devices. Compared with: Standard in-person smoking cessation care. Monocentric; specific location not stated.
Primary outcomes will be Continuous Abstinence Rates and Point Prevalence Abstinence assessed at 6 and 12 months Experimental group will receive telemedicine-assisted rehabilitation integrated with wearable monitoring devices Control group will receive standard in-person smoking cessation care
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This protocol describes a future trial comparing telemedicine with wearable devices to standard in-person care for smoking cessation. Clinicians should await results; the protocol itself offers no evidence of efficacy or safety.
This is a registered protocol for a future RCT; no results are presented, making it a pre-trial announcement of study design and intent rather than evidence of effectiveness.
As stated by the source record.
Quoted from the source exactly as published.
This protocol describes a future trial comparing telemedicine with wearable devices to standard in-person care for smoking cessation. Clinicians should await results; the protocol itself offers no evidence of efficacy or safety.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Tobacco smoking remains one of the leading preventable causes of morbidity and mortality worldwide and is associated with cardiovascular, respiratory, oral, and psychological disorders. Although conventional smoking cessation interventions are effective, barriers related to accessibility, adherence, healthcare costs, and continuity of care frequently limit long-term success. Recent advances in technology may offer innovative opportunities to improve multidisciplinary smoking cessation pathways. METHODOLOGY: The Wear-Smile project is a non-profit, monocentric, randomized controlled trial registered in the Clinical Trial Protocol Registry and Results System (code No.: NCT07593742), designed to evaluate the effectiveness of a multidisciplinary telemedicine-based smoking cessation program assisted by wearable remote-monitoring devices. Adults who smoke combustible or heated tobacco or electronic nicotine delivery systems will be randomly allocated in a 1:1 ratio to either an experimental group receiving telemedicine-assisted rehabilitation integrated with wearable monitoring devices or a control group receiving standard in-person smoking cessation care. The intervention will include a multidisciplinary behavioral smoking cessation intervention involving cardiology, respiratory, dental, and psychology specialists. Primary outcomes will include Continuous Abstinence Rates and Point Prevalence Abstinence assessed at 6 and 12 months. Secondary outcomes will include cardiopulmonary and oral health parameters, smoking-related variables, health- and oral health-related quality of life (QoL), as well as adherence, usability, acceptability, and satisfaction with the rehabilitation program. CONCLUSIONS: The project may provide preliminary evidence regarding the potential feasibility, acceptability, and effectiveness of a multidisciplinary smoking cessation program integrating telemedicine and wearable monitoring technologies in improving abstinence outcomes, patient engagement, continuity of care, and QoL.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.